Google
PACB 株価分析 — Pacific Biosciences of California (Healthcare >> Medical Devices)
PACB に関するよくある質問
PACBのROE（自己資本利益率）は？
Pacific Biosciences of CaliforniaのROEは-5,434.32%です。
PACBの配当利回りは？
Pacific Biosciences of Californiaの配当利回りは0.00%です。
PACBの品質スコア（Quality Score）は？
当社のAIはPACBの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
PACBは今が買い時ですか？
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
PACBはどのセクターに属しますか？
Pacific Biosciences of CaliforniaはHealthcare >> Medical Devicesセクターに分類されます（NASDAQ市場）
PACB AI Analysis Summary
Our AI summary for PACB: Pacific Biosciences of California (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 0.00, ROE of -5,434.32%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.44
Price
0.02
(1.41%)
Day Change
|
|
|---|
PACB, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.44 |
| PBV / Sector |
186.41 / -104.79
|
| Earning Per Share | -0.42 |
| PE / Sector |
N/A / 32.46
|
| PEG or PE/Growth / Sector |
N/A / 0.47
|
| Average 1M Daily Value |
8.47 M
|
| Average 1W Daily Value |
6.59 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:39 |
| Symbol | PACB |
| Name | PACIFIC BIOSCIENCES OF CALIFORNIA |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 310.60 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 441.05 / 20,480.80 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1305 O?Brien Drive, Menlo Park, CA, United States, 94025
Phone: 650 521 8000
Website: https://www.pacb.com
Employees: 485
Sector: Healthcare >> Medical Devices
Description: Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
